Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First-Line Breast Cancer Approval Opens The Door For Pfizer’s Palbociclib

This article was originally published in The Pink Sheet Daily

Executive Summary

The CDK 4/6 inhibitor Ibrance (palbocliclib) just got its first approval in first-line metastatic breast cancer and Pfizer is losing no time on development, with trials of other indications planned or ongoing, including different tumor types.

You may also be interested in...



10 Triumphant Drug Launches Of The Decade

The view from 2020: Scrip looks back at the most successful commercial launches of the decade.

And Then There Were Three: Lilly's Verzenio Approved For Breast Cancer

Lilly will be offering its Verzenio – the third CDK4/6 inhibitor to reach the US market – at a comparable list price to Pfizer's Ibrance and Novartis' Kisqali. FDA granted the drug a swift approval, just two months after it was accepted for priority review.

Lilly Preps Abemaciclib To Take On Ibrance; Differentiation Still A Question

The CDK4/6 inhibitor showed progression-free survival in patients with breast cancer in an interim analysis, and Lilly plans to begin global regulatory submissions for the drug in the second quarter.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS078222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel